Other Grant Opportunities
These are grant opportunities offered by organizations other than HTRS.
Please contact the organization mentioned in the listing for more information.
New NHLBI FOA: The Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed) which was recently published in the NIH Guide.
The FOA number is RFA-HL-20-014 and the web page is: https://grants.nih.gov/grants/guide/rfa-files/rfa-hl-20-014.html
This program will provide opportunities to advance rare disease research using genetics and deep phenotyping to characterize the disease and to identify disease sub-types; to use data science methods that integrate clinical and patient-reported outcomes with laboratory, imaging, environmental and -omics data to understand the natural history of disease; to generate data that differentiate patients with the same morphological phenotype but different genetic mutations and severity of outcomes; to elucidate genotype-phenotype interactions and multisystem phenotyping to develop reliable and valid predictive tools to determine who will respond to which treatments and when to intervene; and to encourage innovative methods such as telemedicine to include participants with rare diseases located in remote locations.
2019 Pfizer ASPIRE Hemophilia Research Awards
Pfizer is proud to announce the Advancing Science through Pfizer -- Investigator Research Exchange (ASPIRE) 2019 Investigator Awards in Hemophilia Research, a competitive, peer-reviewed grants program sponsored by Pfizer for investigators in the United States.
Funding opportunity: up to $125,000 per year (for up to two years)
Application Deadline: Friday, April 19, 2019
• To support basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the pathogenesis and treatment of hemophilia
• To support academic research along with the career development of promising young and established scientists
Area of Research Focus
Pfizer will consider applications that address one of the following areas in Hemophilia A and/or Hemophilia B (applications comprising laboratory investigation or clinical research will be considered):
• Real-world analyses (including factor-related expenditures, dispensation, and usage) of standard versus extended half-life factor replacement products
• Clinical outcomes associated with on-demand use of standard half-life factor replacement products, including for breakthrough bleeding episodes while on established prophylactic regimens (factor replacement or non-factor replacement-based)
• Outcomes associated with physical activity/exercise and coordination of preventative factor regimens using standard half-life factor replacement products*
• Clinical outcomes, patient-reported outcomes, and resource utilization (including HTC-specific) in mild hemophilia
• Scientific aspects of AAV-based gene therapy for hemophilia, including neutralizing antibodies to AAV vectors and characteristics of immune response following treatment
* to include moroctocog alfa and/or nonacog alfa
Application and Selection Process
The 2019 US Hemophilia ASPIRE Program is open to US early-career or established investigators for clinical research/basic science in hemophilia. Review of applications will be performed by an independent, external panel of experts. Project duration should be one or two years and the annual approximate award should not exceed a maximum of $125,000/year, inclusive of overhead costs (capped at 28%). Application Deadline: Friday, April 19, 2019.
For more info, visit https://www.pfizer.com/purpose/independent-grants/competitive-grants
Open RFPs: Hemophilia ASPIRE 2019 (United States)
2019 NASTH Research Fellowship Applications are Now Open
Applications are now open for the 2019 NASTH Sponsored Research Fellowships, an 8 – 10 week program for medical, PhD, MD/PhD, or PharmD students working on targeted research projects in hemostasis and thrombosis. Proposed projects may be lab-based, clinical or epidemiologic in design. The program includes a $5,000 fellowship stipend plus a $2,000 travel allowance, collaboration with a research mentor, and a presentation at a 2020 professional meeting. Applications are now open. The application deadline has been extended to March 1, 2019. Up to three fellowships will be awarded. More Information
As part of the NASTH Fellowship Program, students are paired with research mentors. Responsibilities include assisting the applicant with the development of a research project plan, and then if the applicant is successful, overseeing the research project and providing career guidance and support. Mentors/their labs receive a $1,000 stipend. If you are willing to serve as a mentor, please email us ([email protected]) at your earliest convenience, and include your research area (platelets, coagulation & fibrinolysis, vascular biology, thrombotic or hemorrhagic disorders) and whether your focus is clinical, basic, translational, epidemiology or public health.
NIH Bridge Award - Apply Today
Funding amount: $125,000 for one year
Application Deadline: August 20, 2018
If you applied for an NIH R01 grant or equivalent federal grant but were denied funding, NHF’s Bridge Award can help you continue your research. This grant seeks to help hematology investigators continue their critical research into inheritable bleeding disorders and contribute to their retention in bleeding disorders investigation.
NHF Innovative Investigator Award - Apply Today
Funding amount: Up to $60,000 per grant for a period of 12-18 months.
Application Deadline: September 24, 2018
NHF is seeking innovative investigator research projects that demonstrate a commitment to the bleeding disorders community and support NHF’s goal to develop outcomes-related data. Open to all multidisciplinary team members within the federally-funded HTC network, we encourage projects that promote the development of novel technologies and/or therapies to advance the field of bleeding disorders research.
THSNA Travel-To-A-Mentor Award Call for Applications
Each THSNA Travel-To-A-Mentor Award provides financial support (up to $2,500 per award) for one mentee to train for one week with a pre-selected research mentor at the mentor's facility anywhere in the US, Canada, or Mexico. Award funds will cover transportation, hotel/housing, meals, and essential incidental expenses.
Applicants must be a member of a THSNA member organization. HTRS is a member of THSNA.
The structure of each one-week experience will be determined jointly by the mentee and mentor, and is expected to include:
a) clinical and/or laboratory experiences (where applicable)
b) attendances at relevant conferences and laboratory or research group meetings
c) a meeting with the mentor to discuss potential future collaborations
Awards will fall into the following categories:
- Laboratory technologist/specialist
- PhD researcher
- Physician investigator, clinical, translational, or basic
- Patient advocate
Please find below the link to the complete Award Outline and Application Link.
For questions or assistance with locating a mentor, please contact THSNA at:
Email: [email protected]
NHBLI Grant Opportunities - submission deadlines for 2018 have passed
The NHLBI Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Funding Opportunity Announcements (FOAs) have been recently published in the NIH Guide:
The purpose of these FOAs is to provide support for planning activities for late phase (phase II and beyond) single-site or multi-site investigator-initiated clinical trials that address critical clinical questions within the mission of the National Heart, Lung, and Blood Institute (NHLBI) and that require non-traditional clinical trial designs with the opportunity for statistical novelty and/or innovation.
Examples of scientific areas / clinical questions for which alternative approaches may be required:
- studies of rare diseases and/or therapeutics
- studies in sub-populations of more common diseases, e.g. precision medicine trials
- late-stage implementation research
- interventional trials for which
- non-randomized study setting is required
- optimal treatment control arm may be difficult to implement
- innovative design and analysis would result in optimizing trial efficiency and cost
The submission deadlines for 2018 have passed.
For any questions about these FOAs from potential applicants planning a clinical trial in an area of blood science that is within the mission of NHLBI, please contact:
Dr Andrei Kindzelski, [email protected]